Warfarin was initially sold as rat poison as it was so effective at causing internal bleeding in rodents
A.KwonW
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
History of Pancreatitis: Relative contraindication Type 1 Diabetes Gastroparesis Pregnancy and Breastfeeding Diabetic Retinopathy If youre ready to explore whether a GLP-1 agonist or other medication is right for you, schedule your consultation and InBody scan with us today
SIRT3 lysine deacetylase inhibitors specifically target SIRT3 without affecting its structurally similar counterparts, SIRT1 and SIRT2 185,186
This is not an independently verified or audited statistic